Cellectis Presents Breakthrough in Fight Against Cancer at ESGCT Congress
10/29/2012 6:41:43 AM
PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (Alternext: ALCLS), the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris. The project is led by Dr. Andrew Scharenberg, Chief Scientific Officer of Cellectis therapeutics, a Cellectis Group subsidiary. Dr. Scharenberg is an immunology specialist at Seattle Children’s Hospital in the United States and a professor of pediatrics and immunology at the University of Washington.
comments powered by